$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Microchip Technology shows early signs of recovery with sequential sales growth and improved inventory, but persistent margin pressures and macro risks temper the outlook.

# Microchip Technology Q1 FY2026: Sequential Recovery Signals Early Turnaround, but Margin Pressures Persist

---

## Executive Summary

- **Microchip Technology Inc. (MCHP) delivered Q1 FY2026 net sales of $1.08B, up 10.8% sequentially,** signaling a rebound from recent lows, but still down 13.4% YoY. The sequential beat was driven by normalized inventory management and disciplined pricing, not by one-off events.
- **Non-GAAP EPS of $0.27 fell sharply from $0.53 YoY,** reflecting ongoing operational headwinds and margin compression, despite the top-line recovery. Gross margins contracted meaningfully, with GAAP gross margin at 53.6% (down 580 bps YoY).
- **Management struck a cautiously optimistic tone,** highlighting a “trifecta effect” of inventory correction, improved sell-in/sell-through alignment, and operational leverage. Q2 FY2026 guidance calls for further sequential growth and incremental margin expansion, but remains conservative given macro headwinds.
- **Risks remain elevated:** macroeconomic uncertainty, supply chain constraints (lead times 6–12 weeks), and competitive pricing continue to pressure profitability. However, aggressive inventory reduction, strong bookings, and emerging design wins in AI/data center and defense offer upside not fully reflected in current valuation.
- **Catalyst watch:** Q2 FY2026 results (guidance implies 5%+ sequential growth), further margin recovery, and updates on backlog/bookings momentum will be key for sentiment.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change   |
|-----------------------|------------|-----------|----------|--------------|
| Revenue               | $1.0755B   | $1.07B    | +0.5%    | -13.4%       |
| Non-GAAP EPS          | $0.27      | $0.26     | +3.8%    | -49.1%       |
| GAAP Gross Margin     | 53.6%      | 54.0%     | -0.4pp   | -5.8pp       |
| Non-GAAP Gross Margin | 54.3%      | 54.5%     | -0.2pp   | -5.6pp       |
| Inventory Reduction   | $124.4M    | —         | —        | +Efficiency  |
| Dividend Paid         | $245.5M    | —         | —        | +Sustained   |

---

## Earnings Quality

- **Revenue mix improved sequentially** as normalized inventory and disciplined pricing drove volume gains, but YoY sales remain pressured by weak end-market demand.
- **Margins compressed sharply:** GAAP gross margin fell to 53.6% (from 59.4% YoY), and Non-GAAP gross margin to 54.3% (from 59.9% YoY), reflecting higher COGS, restructuring costs (layoffs, pay cuts, factory closures), and underutilization.
- **Operating income contracted:** GAAP operating income dropped to $32.1M (from $350.2M YoY), and Non-GAAP operating income to $222.3M (from $430.7M YoY), highlighting the divergence between sales recovery and profitability.
- **Balance sheet efficiency improved** with a $124.4M inventory reduction, but this also signals ongoing cost adjustments and cautious demand management.

---

## Management Commentary & Guidance

- **Management tone:** Cautiously bullish, emphasizing the “trifecta effect” of inventory correction, improved channel alignment, and operational leverage. Management acknowledged YoY challenges but stressed sequential momentum and early signs of demand recovery.
- **Q2 FY2026 guidance:** Net sales of $1.110B–$1.150B (implying ~5.1% sequential growth), Non-GAAP gross margin of 55.0%–57.0%, and Non-GAAP operating margin of 22.2%–24.6%. Guidance is above typical seasonality but remains conservative given macro and margin headwinds.
- **Assumptions:** Recovery driven by backlog strength (highest bookings in three years), continued inventory normalization, and early traction in AI/data center and defense verticals.

---

## Key Risks

- **Cost inflation and margin pressure:** Higher input costs, restructuring expenses, and underutilization continue to weigh on margins.
- **Demand-side risks:** Macro uncertainty, global economic weakness, and elongated supply chain lead times (6–12 weeks) could limit near-term upside.
- **Competitive pressures:** Pricing discipline is holding, but competitive intensity remains high, especially in core microcontroller and analog segments.

---

## Expected Market Reaction

- **Investor sentiment likely mixed:** Sequential revenue and working capital improvements may drive a modest positive reaction, but YoY declines in revenue, EPS, and margins could temper enthusiasm.
- **Analyst commentary:** Some may argue the market is underestimating the impact of effective inventory management and the potential for margin recovery, while others may focus on persistent macro and margin risks.

---

## Final Takeaway

- **Q1 FY2026 was a transitional quarter for Microchip Technology:** Sequential growth and improved balance sheet efficiency signal early recovery, but margin compression and YoY declines highlight ongoing fragility.
- **Market may be underpricing the upside from inventory normalization, backlog strength, and emerging design wins** in AI/data center and defense, while overemphasizing near-term macro and margin risks.
- **Catalysts ahead:** Q2 FY2026 results (sequential growth and margin recovery), updates on backlog/bookings, and progress in high-growth verticals (AI/data center, defense) will be critical for re-rating the stock.

Microchip (MCHP): Early Recovery, Margin Headwinds Persist

Microchip Technology is poised for a sequential recovery in Q1 FY2026, with improving bookings, leaner inventory, and disciplined capex likely driving margin expansion and potential upside to consensus expectations.

# Microchip Technology Incorporated: Sequential Recovery in Focus—Q1 FY2026 Earnings Outlook

## Executive Summary: Bullish on Sequential Recovery, Margin Leverage in Q1 FY2026

We hold a **Bullish** outlook for Microchip Technology Incorporated’s upcoming Q1 FY2026 results, anticipating a modest but meaningful sequential rebound in both revenue and margins. Management’s guidance for **net sales of $1.02B–$1.07B** and **GAAP gross margin of 51.2%–53.2%** signals a clear inflection from the Q4 FY2025 trough. Notably, the **book-to-bill ratio of 1.07** and a sharp reduction in distribution inventory days to **33** underscore improving demand and operational discipline. The market may be underestimating the **earnings leverage from aggressive cost controls and selective capex discipline**, which could drive upside to consensus EPS if demand momentum persists.

## Recent Trends Signal What’s Next: Revenue and Margin Bottoming, Bookings Rebound

Microchip’s last two quarters reveal a bottoming in revenue and a nascent recovery in margins. **Q4 FY2025 revenue of $970.5M** marked the cycle low, but Q1 guidance implies a **5–10% sequential increase**. Gross margin, which dipped to **51.6% in Q4**, is guided to rebound to as high as **53.2%**. The **book-to-bill ratio improved to 1.07** in Q4, and distribution inventory days fell to **33**, both positive leading indicators.

### Quarterly Financial Trend Table

| Quarter         | Revenue ($M) | GAAP Gross Margin | Operating Margin | EPS (GAAP) |
|-----------------|--------------|------------------|------------------|------------|
| Q3 FY2025       | 1,295.8      | 67.1%            | 36.2%            | $1.16      |
| Q4 FY2025       | 970.5        | 51.6%            | 0.2%             | $0.00      |
| Q1 FY2026 (G)   | 1,020–1,070  | 51.2–53.2%       | 0.2–3.9%         | Break-even to positive |

**Trend:** The table highlights a sharp Q4 revenue/margin trough, with Q1 guidance pointing to sequential improvement.

## Management’s Forward Tone and Positioning: From Defensive to Constructively Optimistic

Management’s Q4 FY2025 commentary marked a clear shift from caution to optimism. CEO Ganesh Moorthy stated, **“We are finally calling the last quarter as a revenue bottom,”** and emphasized, **“We are very confident in our ability to leverage margins as demand recovers.”** This is a notable pivot from prior quarters’ language around “challenging demand” and “uncertainty.” The focus on “tremendous leverage” and “operational discipline” signals a proactive approach to margin recovery and cost containment, setting a higher bar for Q1 execution.

## KPI Trends & Upcoming Quarter Drivers: Bookings, Inventory, and Capex Discipline

Three KPIs will be pivotal for Q1 FY2026:

- **Book-to-Bill Ratio:** Improved to **1.07** in Q4, with record April bookings, suggesting revenue upside.
- **Distribution Inventory Days:** Fell to **33** in Q4, with management targeting continued low levels, supporting working capital efficiency.
- **Capex:** Q4 spend was **$14.2M** (down sharply YoY), with Q1 guidance of **$20M–$25M**, reflecting targeted investment in assembly/test.

### KPI Movement Table

| KPI                        | Q4 FY2024 | Q4 FY2025 | Q1 FY2026 (G) | YoY Change | QoQ Change |
|----------------------------|-----------|-----------|---------------|------------|------------|
| Book-to-Bill Ratio         | 0.98      | 1.07      | >1.0          | +0.09      | +0.09      |
| Distribution Inventory Days| 45        | 33        | ~33           | -12        | 0          |
| Capex ($M)                 | 38.0      | 14.2      | 20–25         | -17.0      | +6–11      |

**Impact:** Higher bookings and leaner inventory support revenue growth and margin expansion; disciplined capex underpins cost control.

## Missed by the Street: Operational Urgency and Hidden Margin Upside

A subtle but critical insight from recent filings is management’s **“extreme sense of urgency”** in cost control and capacity adjustments. This is not just rhetoric—Q4 saw a **$62.8M inventory reduction** and a sharp capex pullback. The Street may be underappreciating the **potential for margin outperformance** if these operational levers yield faster-than-expected cost absorption as demand recovers.

## Scenarios for the Upcoming Quarter: Bull, Base, and Bear Cases

### Q1 FY2026 Scenario Table

| Scenario | Revenue ($M) | GAAP EPS      | GAAP Gross Margin | Operating Margin | Key Assumptions                                              |
|----------|--------------|--------------|-------------------|------------------|--------------------------------------------------------------|
| Bull     | 1,070        | Break-even+  | 53.2%             | 3.9%             | Strong bookings convert, margin recovery, no macro shocks    |
| Base     | 1,040        | Near break-even| 52.0%            | 2.0%             | Sequential improvement, steady cost control                  |
| Bear     | 1,020        | Negative     | 51.2%             | 0.2%             | Macro headwinds, slower inventory burn, muted demand         |

**Most Likely:** The **Base case** is most probable, given current bookings, inventory trends, and management’s measured optimism. However, upside risk exists if April’s booking strength persists.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Table

| Quarter         | Revenue ($M) | GAAP EPS | GAAP Gross Margin | Operating Margin |
|-----------------|--------------|----------|-------------------|------------------|
| Q3 FY2025       | 1,295.8      | $1.16    | 67.1%             | 36.2%            |
| Q4 FY2025       | 970.5        | $0.00    | 51.6%             | 0.2%             |
| Q1 FY2026 (G)   | 1,020–1,070  | 0.00–0.05| 51.2–53.2%        | 0.2–3.9%         |

### KPI Movement Table

| KPI                        | Q4 FY2024 | Q4 FY2025 | Q1 FY2026 (G) |
|----------------------------|-----------|-----------|---------------|
| Book-to-Bill Ratio         | 0.98      | 1.07      | >1.0          |
| Distribution Inventory Days| 45        | 33        | ~33           |
| Capex ($M)                 | 38.0      | 14.2      | 20–25         |

### Key Management Quotes

1. **“We are finally calling the last quarter as a revenue bottom.”**  
   *Q4 FY2025 Earnings Call*  
   *Signals management’s conviction that the cyclical downturn has ended.*

2. **“We are very confident in our ability to leverage margins as demand recovers.”**  
   *Q4 FY2025 Earnings Call*  
   *Implies margin expansion is a near-term priority.*

3. **“We have an extreme sense of urgency in cost control and capacity adjustments.”**  
   *Q4 FY2025 Earnings Call*  
   *Highlights aggressive operational discipline, a potential upside lever.*

4. **“Record bookings in April give us confidence in sequential revenue growth.”**  
   *Q4 FY2025 Earnings Call*  
   *Supports the bullish revenue guidance for Q1.*

5. **“Capex will remain focused and disciplined, targeting $20M–$25M in Q1.”**  
   *Q4 FY2025 Earnings Call*  
   *Indicates continued fiscal prudence, supporting margin stability.*

6. **“Distribution inventory days are at multi-year lows, positioning us well for recovery.”**  
   *Q4 FY2025 Earnings Call*  
   *Suggests lean channel inventory, reducing risk of future write-downs.*

7. **“We remain vigilant on macro risks, including tariffs and FX volatility.”**  
   *Q4 FY2025 Earnings Call*  
   *Acknowledges external risks that could temper upside.*

---

**Conclusion:**  
Microchip Technology enters Q1 FY2026 with clear signs of bottoming and early recovery. Investors should focus on bookings momentum, inventory discipline, and management’s operational urgency as key drivers for upside surprise. The risk/reward skews positive, with margin leverage and cost controls potentially delivering more than the Street currently expects.

Microchip (MCHP): Sequential Recovery and Margin Upside